2. 筋萎縮性側索硬化症 Amyotrophic lateral sclerosis Clinical trials / Disease details
臨床試験数 : 645 / 薬物数 : 589 - (DrugBank : 163) / 標的遺伝子数 : 150 - 標的パスウェイ数 : 225
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05136885 (ClinicalTrials.gov) | February 21, 2022 | 14/11/2021 | HEALEY ALS Platform Trial - Regimen E SLS-005 - Trehalose | HEALEY ALS Platform Trial - Regimen E SLS-005 - Trehalose | Amyotrophic Lateral Sclerosis | Drug: SLS-005;Drug: Matching Placebo | Merit E. Cudkowicz, MD | Seelos Therapeutics, Inc. | Enrolling by invitation | 18 Years | N/A | All | 160 | Phase 2/Phase 3 | United States |
| 2 | NCT04297683 (ClinicalTrials.gov) | July 14, 2020 | 3/3/2020 | HEALEY ALS Platform Trial - Master Protocol | HEALEY ALS Platform Trial | Amyotrophic Lateral Sclerosis | Drug: Zilucoplan;Drug: Verdiperstat;Drug: CNM-Au8;Drug: Pridopidine;Drug: SLS-005 Trehalose | Merit E. Cudkowicz, MD | Massachusetts General Hospital | Recruiting | 18 Years | N/A | All | 800 | Phase 2/Phase 3 | United States |